No Medication for Stimulant Use Disorder: How Residential Treatment Is Planned for Meth and Cocaine, and What to Ask Admissions

When a family calls about methamphetamine or cocaine, one of the first questions is usually some version of “What medication will they put him on?” For opioids or alcohol, there is a real answer. For stimulants, there is not, and that single fact changes how a residential stay should be planned, how long it should run, and what has to be in place on discharge day. This post walks through those planning decisions in the order admissions actually works through them.

The Short Answer: No Medication Exists Yet

According to the National Institute on Drug Abuse (NIDA), there is no FDA-approved medication for methamphetamine use disorder or for any other stimulant use disorder, including cocaine. NIDA reports that stimulant withdrawal symptoms typically peak two to three days after last use and may last about a week, while low mood, anxiety and cravings can continue for several months. Because there is no medication to bridge that gap, residential treatment for stimulant use disorder relies on behavioral treatment, with contingency management the best-studied option, alongside cognitive behavioral therapy, group support and motivational interviewing.

That paragraph is the whole planning problem in miniature. The acute phase is short. The vulnerable phase is long. And the tool that carries people through the long phase with opioids, a daily medication, does not exist here yet.

What We See in the First Week

In our admissions work, the stimulant intake that worries families most is often the quiet one. A person who arrived agitated and talking fast is, by day two or three, sleeping most of the day, eating everything on the tray and saying very little. Families on the phone read that as either “he’s fine now” or “something is wrong.” Usually it is neither. It is the crash phase NIDA describes, and it is the point where people most often decide they no longer need to be here, because the chaos that brought them in has gone quiet.

The second pattern is the one that matters for discharge planning: in our experience, a few weeks in, after sleep and appetite settle, cravings tend to return in a different form, cued by a song, a payday, a particular freeway exit. A plan built only around the first week misses this entirely.

Why Stimulant Plans Look Different

These are the mechanisms our clinical team plans around when a stimulant is the primary substance:

• No medication bridge: without an FDA-approved medication, nothing pharmacological holds cravings down after discharge, so the behavioral plan has to be stronger and start earlier.
• Short acute phase, long tail: withdrawal peaks within days, but NIDA notes mood and craving symptoms can last months, which is why length of stay should not be set by how someone looks on day seven.
• Misleading recovery of energy: once sleep normalizes, people often feel better than they have in years, and that feeling is frequently mistaken for being finished with treatment.
• Cue-driven cravings: stimulant cravings are strongly tied to people, places and routines, so the relapse-prevention plan has to name specific cues rather than general “triggers.”
• Hidden polysubstance use: many people who use stimulants also use alcohol, benzodiazepines or opioids to come down, and that second substance can carry the greater medical risk.

The Safety Piece Admissions Must Hear

Stimulant withdrawal itself is rarely medically dangerous in the way alcohol withdrawal is, but the substances people use alongside stimulants can be. Alcohol and benzodiazepine withdrawal carry a risk of seizures and require medical supervision. If your loved one drinks heavily or takes Xanax, Klonopin, Valium or similar medications to sleep after using, tell admissions on the first call. That information changes whether medical detox is needed before residential care.

NIDA also notes that methamphetamine, alone or combined with fentanyl, contributes to the overdose crisis. Anyone who uses stimulants from an unregulated supply should have naloxone available, and anyone returning home after reduced use faces changed tolerance.

The crash phase can bring heavy depression. If someone talks about suicide, call or text 988. If there is chest pain, a seizure, severe confusion or psychosis, call 911.

Questions to Ask on the Admissions Call

Here is something you can do today. Before you commit to any program, ask these five questions and write down the answers:

1. “How do you treat stimulant use disorder specifically?” Listen for named approaches such as contingency management or cognitive behavioral therapy, not just “individual and group therapy.”
2. “How is length of stay decided?” A good answer references clinical reassessment over time, not a fixed number of days that happens to match an insurance authorization.
3. “What happens if they want to leave on day three?” Ask what staff actually do, and whether family will be contacted if the person has signed consent.
4. “Do you screen for alcohol and benzodiazepine use at intake?” The answer should be yes, with a clear path to medical detox if needed.
5. “What does the step-down plan look like?” Ask whether they arrange outpatient treatment or intensive outpatient care before discharge, with a first appointment date already set.

If you want to talk through these with someone before calling anywhere else, our team is available at (877) 328-1968.

How Length of Stay Gets Decided

For stimulant use disorder, length of stay in residential treatment is driven by clinical criteria, typically the ASAM dimensions, rather than by withdrawal severity, because withdrawal is usually over within the first week. What clinicians are actually watching after that is relapse risk, the home environment and whether the person can name and manage their own cues.

Insurance authorizations are often issued in short blocks and reviewed. That is normal. What families should know is that a utilization review asking “why is this person still here if withdrawal is over?” is answered with documentation about relapse risk and recovery environment, not withdrawal. If you are unsure what your plan covers, you can verify insurance benefits before admission so there are no surprises at the first review.

Contingency Management: What It Is and How to Ask

Contingency management offers small, tangible incentives, such as vouchers or gift cards, for verified progress such as negative drug tests or attendance. NIDA describes it as the best-studied behavioral treatment for methamphetamine use disorder and the one most associated with treatment success. It can feel counterintuitive to families. It works in part because stimulants hijack the brain’s reward system, and small, immediate, predictable rewards help rebuild that system around something other than the drug.

Availability varies by program and payer. Ask directly whether it is offered during residential care, after discharge, or through a referral, and who pays for the incentives.

Discharge Without a Prescription

When someone leaves residential treatment for opioid use disorder, a medication often travels with them. With stimulants, the discharge plan has to carry that weight instead. Before discharge day, confirm in writing:

• The date and time of the first outpatient or IOP appointment
• A named list of personal cues and the plan for each
• Whether mental health follow-up is scheduled for mood symptoms that may persist
• Where naloxone is kept at home
• Who the person will call in the first 72 hours if cravings spike

SAMHSA’s National Helpline, 1-800-662-HELP (4357), is a free, confidential, 24/7, 365-day-a-year referral service in English and Spanish, and it is a useful backup number to keep on the fridge.

A Note From the Clinical Side

The families who do best with stimulant treatment are usually not the ones who found the perfect program. They are the ones who stopped measuring progress by how their loved one looked in week one and started asking what the plan was for week eight. That shift alone changes the conversation with any treatment team. Learn more about Jonathan Beazley and the clinical approach at Bodhi.

If someone you love is using methamphetamine or cocaine and you are trying to figure out next steps, call us at (877) 328-1968. We can help you sort out level of care, insurance and timing, even if Bodhi turns out not to be the right fit.

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Alcohol and benzodiazepine withdrawal can cause seizures and require medical supervision. If you or someone you know is in crisis, call or text 988, or call 911 in an emergency.